Last reviewed · How we verify
NCT05225428: VERDI
Video Education With Result Dependent dIsclosure
NA trial testing Video Education in Genetic Testing in 1,020 participants. Currently enrolling.
30 April 2026
Quick facts
| Lead sponsor | Dana-Farber Cancer Institute |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 1,020 |
| Start date | 4 August 2022 |
| Primary completion | 30 April 2026 |
| Estimated completion | 1 September 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Video Education
- Genetic Counseling
Conditions studied
- Genetic Testing — all drugs for Genetic Testing →
- Breast Cancer — all drugs for Breast Cancer →
- Ovarian Cancer — all drugs for Ovarian Cancer →
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
Sponsor
Dana-Farber Cancer Institute
Who can join
18 and older, any sex, with Genetic Testing or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Pretest Video Education Versus Genetic Counseling for Patients With Prostate Cancer: ProGen, A Multisite Randomized Controlled Trial.
Rana HQ, Stopfer JE, Weitz M, Kipnis L, et al · · 2023 · cited 14× · PMID 37733980 · DOI 10.1200/op.23.00007 -
Video Education Is an Acceptable Alternative to Pretest Genetic Counseling for Patients With Breast, Ovarian, Pancreatic, and Metastatic Prostate Cancer: Results From a Randomized Study.
Schneider KA, Massingham L, Weitz M, Phornphutkul C, et al · · 2025 · cited 1× · PMID 40209136 · DOI 10.1200/op-24-00809
Verify or expand the search:
- PubMed search for NCT05225428
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Video Education
Trials testing the same drug.
- NCT07229066 — The Effect of Video-Based Education on Colonoscopy Preparation · NA · recruiting
- NCT07210073 — Video Education to Improve Blood Pressure Control in Patients With Ischemic Heart Disease and Hypertension (V-EDUCATE) · NA · completed
- NCT05686694 — Pregnancy on Oral Glucose Tolerance Test Implementation Status, Knowledge, and Anxiety Level · NA · completed
- NCT07216807 — EDUCATE-C: Education on Cirrhosis -- Assessing Text vs Video · NA · completed
- NCT05159726 — Postpartum Video Education · NA · completed
Other recruiting trials for Genetic Testing
Currently open trials in the same condition.
- NCT06926816 — Universal Genetic Testing for Cancer Risk Reduction · NA · recruiting
- NCT04656028 — Genetic Testing and Motivational Counseling for FH · NA · active not recruiting
- NCT04481061 — Engaging Adolescents in Decisions About Return of Genomic Research Results · NA · active not recruiting
- NCT04245176 — Genetic Testing for All Breast Cancer Patients (GET FACTS) · NA · active not recruiting
Other Dana-Farber Cancer Institute trials
Trials by the same sponsor.
- NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
- NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
- NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
- NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
- NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05225428 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
- Last refreshed: 25 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05225428.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing